alexa Systemic Lupus Erythematosus-An Opinion Article | OMICS International
ISSN: 2161-1149
Rheumatology: Current Research

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Systemic Lupus Erythematosus-An Opinion Article

Maria Jose MorenoMartinez*1 and Manuel José Moreno Ramos2

1Maria Jose MorenoMartinez, Rheumatology, Hospital Rafael Mendez, Lorca, Murcia, Spain

2Manuel José Moreno Ramos, Rheumatologist, Hospital Virgen de la, Arrixaca, Murcia Ctra. Madrid-Cartagena, Spain

*Corresponding Author:
MorenoMartinez MJ
Hospital Rafael Mendez
Lorca, Murcia, Spain
Tel: +0034647810640
Email: [email protected]

Received date: October 27, 2015; Accepted date: November 08, 2015; Published date: November 09, 2015

Citation: MorenoMartinez MJ (2015) Systemic Lupus Erythematosus-An Opinion Article. Rheumatology (Sunnyvale) 5:179. doi: 10.4172/2161-1149.1000179

Copyright: © 2015 MorenoMartinez MJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Rheumatology: Current Research


Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that causes frequent hematological disorders. Thrombocytopenia can occur in 30% of patients with SLE according to some series [1]. Typically, such alterations are controlled with classical immunosuppressants such as oral steroids, hydroxychloroquine, azathioprine and others. In some cases requires the use of more aggressive intravenous immunosuppression as cyclophosphamide, steroids and intravenous immunoglobulins, biological drugs or splenectomy [2].

We recently published the case of a 39 year old woman with SLE, severe thrombocytopenia (5000 platelets/microl) and day bleeding, refractory to different treatments (prednisone 0.5 mg/kg, mycophenolate 2 mg/kg/day, azathioprine 100 mg/day and rituximab). After discussing the case with hematology we decided to start therapy with eltrombopag (thrombopoietin-receptor agonist) [3].

Thrombopoietin induce megakaryocyte maturation [1]. In immune thrombocytopenia, autoantibodies produced by autoreactive B cells binding to megakaryocyte membranes could interfere with megakaryocyte maturation, thus resulting in decreased platelet production [2]. It has been shown anti-thrombopoietin antibodies in patients with SLE [4].

Thrombopoietin-receptor agonist is available in many countries for the treatment of chronic immune thrombocytopenia with an insufficient response to others immunosuppressants [5]. There have been reports of thrombocytopenia in patients with SLE who have been treated with these drugs with good results [3,4].

Thrombopoietin-receptor agonists also have side effects such as headache, nasopharyngitis, upper respiratory tract infection, fatigue and thrombosis [6]. In the case of SLE with secondary antiphospholipid syndrome, they have already been reported some cases in which there have been an increase of thrombosis in patients taking eltrombopag [7].

In patients with SLE and thrombocytopenia refractory to other treatments, thrombopoietin-receptor agonists can be a therapeutic alternative, but we must be cautious in patients at high risk of thrombotic events.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 7971
  • [From(publication date):
    December-2015 - Jul 17, 2018]
  • Breakdown by view type
  • HTML page views : 7922
  • PDF downloads : 49

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7